Atty. Dkt. No. Merck-3159

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans-Michael EGGENWEILER

Title: USE OF THIENOPYRIMIDINES

Appl. No. 10/577,908

Filing Date: May 1, 2006

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **Mail Stop SEQUENCE**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino acid sequence disclosures mailed February 9, 2007, please amend the application as follows:

REMARKS

In response to the aforementioned Notice, applicants contend that having thoroughly reviewed the instant application no sequence data under 37 CFR §1.821(a)(2) is present, thus, a Sequence listing is not required (*i.e.*, "[t]hose sequences containing D-amino acids are not intended to be embraced by this definition"). Therefore, Applicants respectfully request removal of said notice, and believe that the present application is now in condition for allowance. Favorable reconsideration of the application is respectfully requested.

Respectfully submitted,

Date April 9, 2007

By /Anthony J. Zelano/

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 Clarendon Blvd. Suite 1400 Arlington, VA 22201

Telephone: 703.812.5333 Facsimile: 703.243.6410 Anthony Zelano Attorney for Applicant Registration No. 27,969

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No for any such fees; and applicants hereby petition for any needed extension of time.